SIGNIFICANCE OF miRNA-185-5P AND miRNA-424-5P AS PROGNOSTIC MARKERS IN PROGRESSION OF EARLY-STAGE ENDOMETRIAL CANCER
DOI:
https://doi.org/10.15407/exp-oncology.2024.03.244Keywords:
endometrioid carcinoma of endometrium, miRNA-185-5p and miRNA-424-5p expression, peripheral blood serum, relapsesAbstract
Aim. To compare the expression of miRNA-185-5p and miRNA-424-5p in tumor cells and peripheral blood serum (PBS) of patients with endometrioid carcinoma of the endometrium (ECE) and to evaluate the significance of these biomarkers in cancer progression. Materials and Methods. The study was conducted on the samples of peripheral blood serum (PBS) and tumor tissue of 58 patients with stage I ECE using clinical and morphological methods and real-time polymerase chain reaction. Results. A significant increase in the levels of circulating and tumor-associated miRNA-424-5p was established in ECE patients with a history of recurrences compared to patients without recurrences. To the contrary, the expression level of miRNA-185-5p increased in the PBS and decreased in the tumor tissue of ECE patients with recurrences compared to the patients without recurrence. In addition, we revealed that the expression levels of the studied miRNAs were associated with the differentiation grade and degree of tumor invasion. We established that miRNA-424-5p levels in PBS could serve as the most significant indicator for predicting the occurrence of recurrence in patients with ECE (AUC = 0.991; Sp 94.0%; Se 99.9%). Conclusions. The expression features of miRNA-185-5p and miRNA-424-5p in the PBS and tumor tissue of patients with ECE are associated with the aggressiveness of cancer course and the risk of recurrence.
References
Soslow RA, Tornos C, Park KJ, et al. Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcat egories in clinical practice: recommendations of the international society of gynecological pathologists. Int J Gynecol Pathol. 2019;38Suppl1(Iss1Suppl1):S64S74. https://doi.org/10.1097/PGP.0000000000000518
Murali R, Davidson B, Fadare O, et al. Highgrade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations. Int J Gynecol Pathol. 2019;38 Suppl1(Iss 1 Suppl 1):S40S63. https://doi.org/10.1097/PGP.0000000000000491
Buchynska LG, Glushchenko NM, Nesina IP, et al. Molecular phenotype of highgrade endometrioid carcinoma of the endometrium. Exp Oncol. 2020;42(4):300305. https://doi.org/10.32471/exponcology.23128852.vol42no4.15450
Buchynska LG, Glushchenko NM, Nespryadko SV, et al. The significance of the expression of the epithelialmes enchymal transition marker Snail1 and its regulator TGFβ1 in the progression of endometrioid carcinoma of the endometry. Oncology. 2023;25(3):194199. https://doi.org/10.15407/oncology.2023.03.194 (in Ukrainian).
Buchynska L, Gordiienko I, Glushchenko N, Iurchenko N. The KRAS, ATR and CHEK1 expression levels in endo metrial cancer are the risk factors predicting recurrence. PLoS One. 2024,26;19(4):e0302075. https://doi.org/10.1371/ journal.pone.0302075
Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic character ization of endometrial carcinoma. Nature. 2013;497(7447):6773. https://doi.org/10.1038/nature12113
Concin N, MatiasGuiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endo metrial carcinoma. Int J Gynecol Cancer. 2021;31:1239. https://doi.org/10.1136/ijgc2020002230
Smith HL, Southgate H, Tweddle DA, Curtin NJ. DNA damage checkpoint kinases in cancer. Expert Rev Mol Med. 2020;22:e2. https://doi.org/10.1017/erm.2020.3
Kabeche L, Nguyen HD, Buisson, R, Zou L. A mitosisspecific and R loop–driven ATR pathway promotes faithful chromosome segregation. Science. 2018;359(6371):108114. https://doi.org/10.1126/science.aan6490
Gralewska P, Gajek A, Marczak A, Rogalska A. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of highgrade ovarian cancer. J Hematol Oncol. 2020;13(1):39. https://doi.org/10.1186/s13045020008746
Vessoni AT, Zhang T, Quinet A. et al. Telomere erosion in human pluripotent stem cells leads to atrmediated mitotic catastrophe. J Cell Biol. 2021;20(6):e202011014. https://doi.org/10.1083/jcb.202011014
Ferragut Cardoso AP, Banerjee M, Nail AN, et al. miRNA dysregulation is an emerging modulator of genomic insta bility. Semin Cancer Biol. 2021;76:120131. https://doi.org/10.1016/j.semcancer.2021.05.004
Peng Y, Croce CM. The role of microRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004. https://doi. org/10.1038/sigtrans.2015.4
Pełka K, Klicka K, Grzywa TM, et al. miR965p, miR1345p, miR181b5p and miR200b3p heterogenous ex pression in sites of prostate cancer versus benign prostate hyperplasiaarchival samples study. Histochem Cell Biol. 2021;155:423433. https://doi.org/10.1007/s00418020019412
Lekka E, Hall J. Noncoding RNAs in disease. FEBS Lett. 2018;592(17):28842900. https://doi.org/10.1002/18733468.13182
IrmakYazicioglu MB. Mechanisms of microRNA deregulation and microRNA targets in gastric cancer. Oncol Res Treat. 2016;39(3):136139. https://doi.org/10.1159/000443224
Buchynska LG, Borykun TV, Iurchenko NP, et al. Expression of microRNA in tumor cells of endmetrioid carci noma of endometrium. Exp Oncol. 2020;42(4):289294. https://doi.org/10.32471/exponcology.23128852.vol42 no4.15522
GalvãoLima LJ, Morais AHF, Valentim RAM, Barreto EJSS. miRNAs as biomarkers for early cancer detection and their application in the development of new diagnostic tools. Biomed Eng Online. 2021;20(1):21. https://doi. org/10.1186/s12938021008579
Babaeenezhad E, Naghibalhossaini F, Rajabibaz M, et al. The roles of microRNA miR185 in digestive tract. Cancers Noncoding RNA. 2022;8(5):67. https://doi.org/10.3390/ncrna8050067
Wang R, Tian S, Wang HB, et al. MiR185 is involved in human breast carcinogenesis by targeting Vegfa. FEBS Lett. 2014;588(23):44384447. https://doi.org/10.1016/j.febslet.2014.09.045
Zhi Q, Zhu J, Guo X, et al. Metastasisrelated miR185 is a potential prognostic biomarker for hepatocellular carci noma in early stage. Biomed Pharmacother. 2013;67(5):393398. https://doi.org/10.1016/j.biopha.2013.03.022
Zhang K, Wang YY, Xu Y, et al. A twomiRNA signature of upregulated miR1855p and miR3625p as a blood biomarker for breast cancer. Pathol Res Pract. 2021;222:153458. https://doi.org/10.1016/j.prp.2021.153458
Shi YJ, Fang YX, Tian TG, et al. Discovery of extracellular vesicledelivered miR1855p in the plasma of patients as an indicator for advanced adenoma and colorectal cancer. J Transl Med. 2023;21(1):421. https://doi.org/10.1186/ s12967023042496
Boren T, Xiong Y, Hakam A, et al. MicroRNAs and their target messenger RNAs associated with endometrial carci nogenesis. Gynecol Oncol. 2008;110(2):206215. https://doi.org/10.1016/j.ygyno.2008.03.023
Yanokura M, Banno K, Iida M, et al. MicroRNAS in endometrial cancer: recent advances and potential clinical ap plications. EXCLI J. 2015;14:190198. https://doi.org/10.17179/excli2014590
Dai W, Zhou J, Wang H, et al. miR4245p promotes the proliferation and metastasis of colorectal cancer by directly targeting SCN4B. Pathol Res Pract. 2020;216(1):152731. https://doi.org/10.1016/j.prp.2019.152731
Liu J, Gu Z, Tang Y, et al. Tumoursuppressive microRNA4245p directly targets CCNE1 as potential prognostic markers in epithelial ovarian cancer. Cell Cycle. 2018;17(3):309318. https://doi.org/10.1080/15384101.2017.1407894
Wang J, Wang S, Zhou J, Qian Q. miR4245p regulates cell proliferation, migration and invasion by targeting dou blecortinlike kinase1 in basallike breast cancer. Biomed Pharmacother. 2018;102:147152. https://doi.org/10.1016/j. biopha.2018.03.018
Du H, Xu Q, Xiao S, et al. MicroRNA4245p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29. Life Sci. 2019;224:111. https://doi.org/10.1016/j.lfs.2019.03.028
Xu SJ, Xu WJ, Zeng Z, Zhang M, Zhang DY. MiR424 functions as potential diagnostic and prognostic biomarker in melanoma. Clin Lab. 2020;66(7). https://doi.org/10.7754/Clin.Lab.2019.190917
Delangle R, De Foucher T, Larsen AK, et al. The use of microRNAs in the management of endometrial cancer: a metaanalysis. Cancers (Basel). 2019;11(6):832. https://doi.org/10.3390/cancers11060832
Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Or- gans. Lyon: IARC, 2014. 307 p.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2(Delta Delta C(T)) method. Methods. 2001;25(4):402408. https://doi.org/10.1006/meth.2001.1262
Wang T, Wang G, Zhang X, et al. The expression of miRNAs is associated with tumour genome instability and pre dicts the outcome of ovarian cancer patients treated with platinum agents. Sci Rep. 2017;7(1):14736. https://doi. org/10.1038/s4159801712259w
Gajek A., Gralewska P, Marczak A, Rogalska A. Current implications of microRNAs in genome stability and stress responses of ovarian cancer. Cancers (Basel). 2021;13(11):2690. https://doi.org/10.3390/cancers13112690
Östling P, Leivonen SK, Aakula A, et al. Systematic analysis of microRNAs targeting the androgen receptor in pros tate cancer cells. Cancer Res. 2011;71(5):19561967. https://doi.org/10.1158/00085472.CAN102421
Iurchenko NP, Glushchenko NM, Buchynska LG. Assessment of DNA status and peculiarities of expression of cy clins D1, E1 and transcription factor E2F1 in cells of epithelial endometrial tumors. Oncology. 2019;21(3):230237. https://doi.org/10.32471/oncology.26637928.t2132019g.7783 (in Ukrainian).
Wen J, Hu Y, Liu Q, et al. miR424 coordinates multilayered regulation of cell cycle progression to promote esoph ageal squamous cell carcinoma cell proliferation. eBioMedicine. 2018;37:110124. https://doi.org/10.1016/j.ebi om.2018.10.043
Schuhn A, Tobar WT, Gahlawat WA, et al. Potential of bloodbased biomarker approaches in endometrium and breast cancer: a casecontrol comparison study. Arch Gynecol Obstet. 2022;306(5):16231632. https://doi.org/10.1007/ s00404022064828
Zhou L, Wang W, Wang F, et al. Plasmaderived exosomal miR15a5p as a promising diagnostic biomarker for early detection of endometrial carcinoma. Mol Cancer. 2021;20(1):57. https://doi.org/10.1186/s12943021013524
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Experimental Oncology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.